Founded in 2014, Immunethep is a spin-off from the University of Porto.

Immunethep has developed an anti-bacterial immunotherapy based on the discovery of a virulence mechanism shared by a set of different pathogenic bacteria.

By addressing an extracellular virulence factor that is highly conserved in the different bacteria, our anti-bacterial immunotherapy elicits protective antibodies against all the serotypes of the referred bacterial pathogens. This way, it will also prevent the emergence of strains which are not addressed by current vaccines that only address structural epitopes.

The first product, PNV1 - Paragon Novel Vaccine, is a preventive strategy that will confer a robust protection against the main life threatening bacterial infections.

Immunethep’s PNV1 will be the first vaccine able to prevent multi-bacterial infections from all its serotypes from the womb until elderhood.